

SUSTAINABILITY DATA 2025

ONO PHARMACEUTICAL CO., LTD.

Environmental Data

[Data Coverage]

Consolidated	All companies included in the consolidated financial statements.	
Non-consolidated	ONO PHARMACEUTICAL CO.,LTD.: Fujiyama Plant/Yamaguchi Plant (since FY2018 -)/Joto Pharmaceutical Product Development Center/ Minase Research Institute/Tsukuba Research Institute/Former Fukui Research Institute/Offices including the Head Office	
ONO Group	FY2024	ONO PHARMACEUTICAL CO.,LTD., ONO PHARMA USA, INC., ONO PHARMA UK LTD., ONO PHARMA KOREA CO., LTD., ONO PHARMA TAIWAN CO., LTD., Ono Pharma UD Co., Ltd., michiteku Co.,Ltd., TOYO Pharmaceutical Co., Ltd., BEE BRAND MEDICO DENTAL. CO., LTD.
	FY2022 and FY2023	ONO PHARMACEUTICAL CO.,LTD., ONO PHARMA USA, INC., ONO PHARMA UK LTD., ONO PHARMA KOREA CO., LTD., ONO PHARMA TAIWAN CO., LTD., Ono Pharma UD Co., Ltd.

• If the data coverage is different from the above, it is specified in each table.

• For FY2024 data coverage, michiteku Co.,Ltd., TOYO Pharmaceutical Co., Ltd., and BEE BRAND MEDICO DENTAL. CO., LTD. are added to those of FY2023.

Due to rounding of the figures in the table, the breakdown totals may not always equal the overall totals (Same as environmental data below)

Scope 1+2 GHG Emissions (Unit: kt-CO₂)

Item		Data Coverage	FY2017 (Base year)	FY2021	FY2022	FY2023	FY2024 <input checked="" type="checkbox"/>
Scope 1 (Breakdown by GHG type)	Energy-derived	Non-consolidated	8.5	9.8	8.0	6.6	7.0
		ONO Group	-	-	8.0	6.6	7.4
	Non-energy-derived (HFCs, HCFCs)	Non-consolidated	0.2	0.0	0.2	0.1	0.6
		ONO Group	-	-	0.2	0.1	0.6
	Total	Non-consolidated	8.7	9.8	8.2	6.7	7.7
		ONO Group	-	-	8.2	6.7	8.1
Scope 2		Non-consolidated	21.1	13.7	10.2	9.4	1.2
		ONO Group	-	-	10.4	9.5	3.1
Scope 1+2 (Total) (a)		Non-consolidated	29.8	23.6	18.4	16.0	8.9
		ONO Group	-	-	18.6	16.2	11.2
Amount of CO ₂ offset due to voluntary credit (Carbon-neutral city gas purchased) (b)		Non-consolidated	0.0	0.6	0.7	1.7	6.9
		ONO Group	-	-	0.7	1.7	6.9
GHG emissions after offset (a-b)		Non-consolidated	29.8	23.0	17.7	14.4	2.0
		ONO Group	-	-	17.9	14.5	4.3

GHG emissions are calculated using the following formula. These are market-based data.

[Japanese bases] Calculated in accordance with the Act on Promotion of Global Warming Countermeasures.

[Overseas bases] Calculated by multiplying the amount of electricity purchased by overseas based by the country-specific emission factor published in the UNFCCC The IFI Dataset of Default Grid Factors (v3.1).

Scope 3 GHG Emissions (Unit: kt-CO₂)

Category		Calculation method / notes	Data Coverage	FY2017 (Base year)	FY2021	FY2022	FY2023	FY2024 <input checked="" type="checkbox"/>
01	Purchased goods and services	Calculated by multiplying the Scope 1+2 and Scope 3 Upstream (category 1 to 8) GHG emissions of our major suppliers of raw materials (covering more than 80% of the purchase price of raw materials) by our transaction volume as a percentage of the sales volume of the suppliers. For suppliers of raw materials other than those mentioned above, the calculation is based on the ratio of GHG emissions to the transaction value of major suppliers ^{*3}	Non-consolidated	56.5 ^{*1}	89.1 ^{*1}	54.4 ^{*1}	59.6 ^{*1}	_ ^{*2}
			ONO Group ^{*8}	-	-	-	64.0	_ ^{*2}
02	Capital goods	Calculated by multiplying the price of capital goods treated as fixed assets (investment in the expansion and maintenance of facilities), excluding land, by the emission factor.	Consolidated	52.6	26.4	21.3	18.4	22.8
03	Fuel- and energy related activities not included in Scope 1 or Scope 2	Calculated by multiplying the amount of purchased electricity (excluding renewable energy ^{*4}) by the emission factor.	Non-consolidated	1.5	3.0	2.8	2.9	2.7
			ONO Group ^{*9}	-	-	-	3.1	3.0
04	Upstream transportation and distribution	Calculated by multiplying the emission factor by the transportation data from our own production sites and distribution centers to the delivery destination ^{*5}	Non-consolidated	0.1	0.1	0.1	0.4 ^{*1}	0.3
			ONO Group ^{*10}	-	-	-	0.5	0.4
05	Waste generated in operations	Calculated by multiplying the weight value of waste by an emission factor for each type of waste.	Non-consolidated	0.3	0.3	0.3	0.3	0.2
			ONO Group ^{*11}	-	-	-	0.3	0.3
06	Business travel	Calculated by multiplying the amount of transportation expenses paid by airplanes and Shinkansen by the emission factor.	Non-consolidated	2.5	0.5	1.3	3.1	4.0
			ONO Group ^{*12}	-	-	-	4.4	4.8

Category		Calculation method / notes	Data Coverage	FY2017 (Base year)	FY2021	FY2022	FY2023	FY2024 <input checked="" type="checkbox"/>
07	Employee commuting	<ul style="list-style-type: none"> Calculated by multiplying the amount paid for commuting transportation by the emission coefficient. Including commuting by car from FY2021 	Non-consolidated	0.4	0.7	0.7	0.7	0.7
			ONO Group*13	-	-	-	0.7	0.8
08	Upstream leased assets	Calculated by multiplying the fuel consumption of leased cars by the emission factor*6	Non-consolidated	3.5	2.1	1.9	1.9	1.7
			ONO Group*14	-	-	-	2.1	1.8
09	Downstream transportation and distribution	Calculated by multiplying the Scope 1+2 GHG emissions of our major pharmaceutical wholesalers by the value of our transactions as a percentage of the sales volume of our major pharmaceutical wholesalers *7	Non-consolidated	5.3	5.5	7.5	7.6	_*2
10	Processing of sold products	Not relevant	-	-	-	-	-	-
11	Use of sold products	Not relevant	-	-	-	-	-	-
12	End-of-life treatment of sold products	Calculated by multiplying the weight of sold product containers and packaging by the emission factor.	Non-consolidated	0.1	0.2	0.2	0.2	0.2
			ONO Group*15	-	-	-	0.2	0.2
13	Downstream leased assets	Calculated by multiplying the floor area of the building in question by the emission factor for each use*7	Non-consolidated	0.3	0.3	0.3	0.3	0.0
14	Franchises	Not relevant	-	-	-	-	-	-
15	Investments	Calculated by multiplying the Scope 1+2 GHG emissions of investee companies by our equity ownership ratio*16.	Non-consolidated	-	-	-	0.4	_*2
Total			Non-consolidated	123.1	128.1	90.8	95.7	_*2
			ONO Group	-	-	-	101.9	_*2

The emission factors used for calculation are figures stated in the "Emission Factor Database on Accounting for Greenhouse Gas Emissions throughout the Supply Chain (FY2017, Ver. 2.4; FY2021, Ver. 3.2; FY2022, Ver. 3.3, FY2023, Ver. 3.4, FY2024, Ver.3.5)," published by the Ministry of the Environment, Government of Japan.
Since only non-consolidated data is available for FY 2017, FY2021, and FY2022, the ONO Group data is indicated as “-”.

*1: Due to revision of the calculation methods, non-consolidated data for Category 1 (FY2017, FY2021, and FY2022), and for Category 4 (FY2023) have been revised. Based on the previous calculation method, GHG emissions for Category 1 in FY2017, FY2021, FY2022, and FY2023 were 8.5 kt-CO₂, 13.8 kt-CO₂, 4.8 kt-CO₂, and 4.3 kt-CO₂, respectively.

[Previous calculation method: Calculated by multiplying the Scope 1+2 GHG emissions of our major suppliers of raw materials (covering more than 80% of the purchase price of raw materials) by our transaction volume as a percentage of the sales volume of the suppliers. For suppliers of raw materials other than those mentioned above, the calculation is based on the ratio of GHG emissions to the transaction value of major suppliers.]

*2: Categories 1, 9, 15, and the total for FY2024 (non-consolidated and ONO group) are not calculated because our major suppliers and pharmaceutical wholesalers had not published their GHG at the time of calculation.

*3: For category 1, GHG emissions for group companies other than non-consolidated are calculated by multiplying the purchase amount of the main products for their business by the emission factor.

*4: For renewable energy, it is limited to sources such as solar and wind power that are provided under the power supply plans contracted with the energy company.

*5: For category 4, GHG emissions for group companies other than the non-consolidated are calculated by multiplying the transportation costs (upstream) paid by each group company by the emission factor. Based on the contractual arrangements between ONO PHARMACEUTICAL CO., LTD. and its group companies, when ONO PHARMACEUTICAL CO., LTD. pays the transportation costs, the GHG emissions are calculated by multiplying those costs by the emission factor, and are counted as ONO PHARMACEUTICAL's Category 4 emissions.

*6: For category 8, GHG emissions for group companies other than the non-consolidated are calculated by multiplying either the amount of fuel consumed or the fuel costs for leased company cars by the emission factor.

*7: For Categories 9 and 13, group companies other than the non-consolidated are not included.

*8: Non-consolidated, Ono Pharma UD Co., Ltd., michteiku Co.,Ltd., TOYO Pharmaceutical Co., Ltd., BEE BRAND MEDICO DENTAL CO., LTD.

*9: Non-consolidated, ONO PHARMA USA, INC., ONO PHARMA UK LTD., ONO PHARMA KOREA CO., LTD., ONO PHARMA TAIWAN CO., LTD., Ono Pharma UD Co., Ltd., TOYO Pharmaceutical Co., Ltd., BEE BRAND MEDICO DENTAL CO., LTD.

*10: Non-consolidated, ONO PHARMA TAIWAN CO., LTD., michteiku Co.,Ltd.(data for FY2023 is not included in the calculation) , TOYO Pharmaceutical Co., Ltd.

*11: Non-consolidated, Ono Pharma UD Co., Ltd. (data for FY2023 is not included in the calculation) , TOYO Pharmaceutical Co., Ltd., BEE BRAND MEDICO DENTAL CO., LTD. (data for FY2023 is not included in the calculation) .

*12: Non-consolidated, ONO PHARMA USA, INC., ONO PHARMA KOREA CO., LTD., ONO PHARMA TAIWAN CO., LTD., michteiku Co.,Ltd. (data for FY2023 is not included in the calculation) , TOYO Pharmaceutical Co., Ltd., BEE BRAND MEDICO DENTAL CO., LTD.

*13: Non-consolidated, ONO PHARMA USA, INC., ONO PHARMA KOREA CO., LTD., ONO PHARMA TAIWAN CO., LTD., Ono Pharma UD Co., Ltd. (data for FY2023 is not included in the calculation) , michteiku Co.,Ltd. (data for FY2023 is not included in the calculation) , TOYO Pharmaceutical Co., Ltd., BEE BRAND MEDICO DENTAL CO., LTD .

*14: Non-consolidated, ONO PHARMA KOREA CO., LTD., ONO PHARMA TAIWAN CO., LTD., Ono Pharma UD Co., Ltd. (data for FY2023 is not included in the calculation) , BEE BRAND MEDICO DENTAL CO., LTD.

*15: Non-consolidated, TOYO Pharmaceutical Co., Ltd., BEE BRAND MEDICO DENTAL CO., LTD.

*16: For Category 15, GHG emissions are calculated based only on the investee companies that disclose their Scope1+2 GHG emissions.

Energy Consumption (Unit: MWh)

Item	Data Coverage	FY2017 (Base year)	FY2021	FY2022	FY2023	FY2024 <input checked="" type="checkbox"/>
Energy consumption	Non-consolidated	89,163.1	99,499.9	86,067.6	82,285.0	83,748.9
	ONO Group	-	-	86,411.7	82,666.1	90,726.7

Total Electricity Consumption and Renewable Energy Usage Rate

Item		Data Coverage	Unit	FY2017 (Base year)	FY2021	FY2022	FY2023	FY2024
Electricity consumption	Private power generation (renewable) (solar power generation)	Non-consolidated	MWh	55.3	61.9	64.4	64.0	63.6
		ONO Group		-	-	64.4	64.0	63.6
	Purchased electricity (renewable, PPA)	Non-consolidated		0.0	0.0	0.0	0.0	533.0
		ONO Group		-	-	0.0	0.0	533.0
	Purchased electricity (renewable)	Non-consolidated		0.0	2,040.0	3,480.0	20,281.2	37,336.4
		ONO Group		-	-	3,480.0	20,281.2	37,336.4
	Private power generation (non-renewable)	Non-consolidated		7,927.0	8,283.7	7,285.0	5,596.7	6,634.1
		ONO Group		-	-	7,285.0	5,596.7	6,634.1
	Purchased electricity (non-renewable)	Non-consolidated		41,820.1	42,833.5	37,821.6	21,543.7	2,756.2
		ONO Group		-	-	343.7	380.7	7,249.2
	Total (total electricity consumption)	Non-consolidated		49,802.4	53,219.2	48,651.0	47,485.5	47,323.4
		ONO Group		-	-	48,994.7	47,866.3	51,816.4
Certificates usage of renewable energy	Solar power generation	Non-consolidated	MWh	0.0	3,937.9	0.0	0.0	0.0
	Biomass power generation			0.0	3,000.0	6,907.0	0.0	0.0
Renewable energy usage*		Non-consolidated	MWh	55.3	9,039.9	10,451.4	20,345.2	37,933.1 <input checked="" type="checkbox"/>
		ONO Group		-	-	10,451.4	20,345.2	37,933.1 <input checked="" type="checkbox"/>
Renewable energy usage rate (renewable energy usage / total electricity consumption)		Non-consolidated	%	0.1	17.0	21.5	42.8	80.2 <input checked="" type="checkbox"/>
		ONO Group		-	-	21.3	42.5	73.2 <input checked="" type="checkbox"/>

* : Renewable energy usage = Private power generation (renewable, solar power generation) + Purchased electricity (PPA, renewable) + Purchased electricity (renewable) + Certificates usage of renewable energy

Water Intake and Discharged Water Volume by Site (Unit: 1,000 m³)

Data Coverage	Site name	Water stress ^{*1}	FY2017 (Base year)		FY2021		FY2022		FY2023		FY2024 <input checked="" type="checkbox"/>	
			Water intake volume	Discharged water volume	Water intake volume	Discharged water volume	Water intake volume	Discharged water volume	Water intake volume	Discharged water volume	Water intake volume	Discharged water volume
Non-consolidated	Fujiyama Plant	Low - Medium risk	205.6	148.6	138.7	110.2	122.9	100.1	115.8	94.6	127.3	98.2
	Yamaguchi Plant	Medium - High risk	- ^{*2}	- ^{*2}	21.6	20.0	22.8	20.9	24.4	22.9	23.8	23.6
	Joto Pharmaceutical Product Development Center	Low - Medium risk	5.5	5.5	3.9	3.9	3.4	3.4	3.7	3.7	3.5	3.5
	Minase Research Institute	Low - Medium risk	51.3	51.3	31.5	31.5	32.2	32.2	30.1	30.0	34.0	32.9
	Tsukuba Research Institute	Medium - High risk	38.7	5.2	6.6	1.9	0.8	0.2	5.0	5.0	3.6	3.2
	Former Fukui Research Institute	Low - Medium risk	8.1	8.1	7.0	7.0	4.7	4.7	0.0	0.0	0.0	0.0
	Offices including the Head Office	Low - Medium risk or Medium - High risk	15.9	15.9	10.0	10.0	9.5	9.5	10.6	10.6	10.4	10.4
	Total		325.1	234.6	219.4	184.5	196.4	171.2	189.6	166.7	202.8	171.9
Group companies ^{*3}		Low - Medium risk	-	-	-	-	-	-	23.5	18.6	17.9	11.9
Total of ONO Group ^{*4}			325.1	234.6	219.4	184.5	196.4	171.2	213.0	185.3	220.7	183.8

^{*1}: Evaluation results based on WRI Aqueduct (baseline, confirmed as of March 2025)

^{*2}: Since the Yamaguchi Plant was built in June 2018, it is not included for FY2017.

^{*3}: Ono Pharma UD Co., Ltd., TOYO Pharmaceutical Co., Ltd., BEE BRAND MEDICO DENTAL CO., LTD.


^{*4}: For FY2017, FY2021, and FY2022, only non-consolidated data is included. For FY2023 and FY2024, data for Ono Pharma UD Co., Ltd., TOYO Pharmaceutical Co., Ltd., and BEE BRAND MEDICO DENTAL CO., LTD. are also included in addition to non-consolidated data.

Water Intake Volume by Source and Discharged Water Volume by Destination (Unit: 1,000 m³)

Item		Data Coverage	FY2021	FY2022	FY2023	FY2024 <input checked="" type="checkbox"/>
Water intake volume	City water	FY2021, FY2022: Non-consolidated FY2023, FY2024: ONO Group*	195.9	180.6	198.8	207.0
	Groundwater		19.6	15.3	13.4	13.0
	Industrial water		3.9	0.5	0.8	0.7
Total of water intake volume			219.4	196.4	213.0	220.7
Discharged water volume	Fresh surface water	FY2021, FY2022: Non-consolidated FY2023, FY2024: ONO Group*	130.2	121.1	117.4	121.8
	Third party destinations		54.3	50.1	67.9	62.0
	Sea		0.0	0.0	0.0	0.0
	Groundwater		0.0	0.0	0.0	0.0
Total of discharged water volume			184.5	171.2	185.3	183.8
Total of water consumption		FY2021, FY2022: Non-consolidated FY2023, FY2024: ONO Group*	34.9	25.2	27.7	36.9

*: Non-consolidated, Ono Pharma UD Co., Ltd., TOYO Pharmaceutical Co., Ltd., BEE BRAND MEDICO DENTAL. CO., LTD.

Waste Management

Item		Data Coverage	Unit	FY2021	FY2022	FY2023	FY2024 
Industrial waste	Waste generated	Non-consolidated	t	479.1	492.8	569.7	818.6
		ONO Group* ¹		-	-	620.6	869.7
	[Waste breakdown] Special management industrial waste (hazardous waste)* ²	Non-consolidated	t	170.3	142.5	145.5	128.4
		ONO Group* ¹		-	-	149.7	133.4
	final landfill disposal	Non-consolidated	t	0.2	0.1	0.1	0.0
		ONO Group* ¹		-	-	6.7	7.9
	final landfill disposal rate	Non-consolidated	%	0.04	0.02	0.02	0.00
		ONO Group* ¹		-	-	1.09	0.91

*1: For FY2023 and FY2024, data for Non-consolidated and TOYO Pharmaceutical Co., Ltd. are included.

*2: Special management industrial waste (hazardous waste) is defined under the Waste Management and Public Cleansing Law as waste that has properties of explosiveness, toxicity, infectiousness, and/or possibly causing damage to human health or the living environment.

Waste data includes logistics centers starting from FY2021, and the former Fukui Research Institute is included up to FY2023.

Social data 2025

ONO PHARMACEUTICAL CO., LTD.

Occurrence of occupational injuries

Item	Scope	Unit	FY2020	FY2021	FY2022	FY2023	FY2024 <input checked="" type="checkbox"/>
Number of lost-time injuries	Non-consolidated (Employees)	Incidents	3	0	1	0	2
	Non-consolidated (Temporary employees)	Incidents	0	0	0	0	5
Lost-time injury frequency rate [※]	Non-consolidated (Employees)	-	0.47	0	0.16	0	0.31
	Non-consolidated (Temporary employees)	-	0	0	0	0	8.13
Number of fatalities due to occupational accidents	Non-consolidated (Employees)	Persons	0	0	0	0	0
	Non-consolidated (Temporary employees)	Persons	0	0	0	0	0

※ Lost-time injury frequency rate = (number of lost-time injuries / total number of actual working hours) x 1,000,000

Independent Practitioner's Assurance Report

September 17, 2025

Mr. Toichi Takino

Representative Director, President & COO

ONO PHARMACEUTICAL CO., LTD.

Tomoharu Hase

Representative Director

Deloitte Tohmatsu Sustainability Co., Ltd.

3-2-3, Marunouchi, Chiyoda-ku, Tokyo

We have undertaken a limited assurance engagement of the sustainability data indicated with ☒ for the year ended March 31, 2025 (the "Sustainability Data") included in the "SUSTAINABILITY DATA 2025 (PDF version)" (the "Report") of ONO PHARMACEUTICAL CO., LTD. (the "Company").

The Company's Responsibility

The Company is responsible for the preparation of the Sustainability Data in accordance with the calculation and reporting criteria adopted by the Company (indicated with the Sustainability Data included in the Report). Greenhouse gas quantification is subject to inherent uncertainty for reasons such as incomplete scientific knowledge used to determine emissions factors and numerical data needed to combine emissions of different gases.

Our Independence and Quality Management

We have complied with the independence and other ethical requirements of the Code of Ethics for Professional Accountants issued by the International Ethics Standards Board for Accountants, which is founded on fundamental principles of integrity, objectivity, professional competence and due care, confidentiality and professional behavior. We apply International Standard on Quality Management 1, *Quality Management for Firms that Perform Audits or Reviews of Financial Statements, or Other Assurance or Related Services Engagements*, and accordingly maintain a comprehensive system of quality management including documented policies and procedures regarding compliance with ethical requirements, professional standards and applicable legal and regulatory requirements.

Our Responsibility

Our responsibility is to express a limited assurance conclusion on the Sustainability Data based on the procedures we have performed and the evidence we have obtained. We conducted our limited assurance engagement in accordance with the International Standard on Assurance Engagements ("ISAE") 3000, *Assurance Engagements Other than Audits or Reviews of Historical Financial Information*, issued by the International Auditing and Assurance Standards Board ("IAASB"), ISAE 3410, *Assurance Engagements on Greenhouse Gas Statements*, issued by the IAASB and the *Practical Guideline for the Assurance of Sustainability Information*, issued by the Japanese Association of Assurance Organizations for Sustainability Information.

The procedures we performed were based on our professional judgment and included inquiries, observation of processes performed, inspection of documents, analytical procedures, evaluating the appropriateness of quantification methods and reporting policies, and agreeing or reconciling with underlying records. These procedures also included the following:

- Evaluating whether the Company's methods for estimates are appropriate and had been consistently applied. However, our procedures did not include testing the data on which the estimates are based or reperforming the estimates.
- Undertaking site visits to assess the completeness of the data, data collection methods, source data and relevant assumptions applicable to the sites.

The procedures performed in a limited assurance engagement vary in nature and timing from, and are less in extent than for, a reasonable assurance engagement. Consequently, the level of assurance obtained in a limited assurance engagement is substantially lower than the assurance that would have been obtained had we performed a reasonable assurance engagement.

Limited Assurance Conclusion

Based on the procedures we have performed and the evidence we have obtained, nothing has come to our attention that causes us to believe that the Sustainability Data is not prepared, in all material respects, in accordance with the calculation and reporting criteria adopted by the Company.

The above represents a translation, for convenience only, of the original Independent Practitioner's Assurance report issued in the Japanese language.